$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
RedHill's partner, the University of Oklahoma, received a five-year, $2.9 million grant from the National Cancer Institute to run clinical trials of RedHill's opaganib combined with CAR T-cell therapy in ultra-high-risk multiple myeloma. The funding covers a Phase 1b safety and dosing trial of up to 18 patients followed by a Phase 2 study of up to 21 additional patients seeking preliminary evidence of effectiveness, with RedHill expected to supply opaganib at no cost to itself.
Key figures
- Drug Name
- opaganib (ABC294640)
- Deal Value Usd
- 2900000
- Phase Of Trial
- Phase 1b and Phase 2
- Grant duration
- five years
- Phase2 enrollment
- up to 21 additional patients
- Phase1b enrollment
- up to 18 patients
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.